Squarepoint Ops LLC Buys Shares of 175,735 Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)

Squarepoint Ops LLC purchased a new position in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 175,735 shares of the biopharmaceutical company’s stock, valued at approximately $206,000. Squarepoint Ops LLC owned about 0.32% of Marinus Pharmaceuticals at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Point72 DIFC Ltd bought a new position in Marinus Pharmaceuticals in the second quarter valued at $28,000. XTX Topco Ltd bought a new stake in Marinus Pharmaceuticals during the second quarter worth about $232,000. Renaissance Technologies LLC purchased a new position in shares of Marinus Pharmaceuticals in the 2nd quarter worth about $727,000. Acadian Asset Management LLC bought a new position in shares of Marinus Pharmaceuticals during the 2nd quarter valued at about $813,000. Finally, Hussman Strategic Advisors Inc. raised its holdings in shares of Marinus Pharmaceuticals by 14.3% during the 2nd quarter. Hussman Strategic Advisors Inc. now owns 84,000 shares of the biopharmaceutical company’s stock valued at $98,000 after buying an additional 10,500 shares in the last quarter. Hedge funds and other institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals Trading Up 6.1 %

Marinus Pharmaceuticals stock opened at $1.75 on Friday. The firm has a market cap of $96.13 million, a P/E ratio of -0.66 and a beta of 1.14. Marinus Pharmaceuticals, Inc. has a 1-year low of $1.05 and a 1-year high of $11.26. The firm has a 50-day moving average of $1.48 and a 200-day moving average of $2.06.

Marinus Pharmaceuticals (NASDAQ:MRNS) last released its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.01). The business had revenue of $8.06 million during the quarter, compared to analysts’ expectations of $9.05 million. Marinus Pharmaceuticals had a negative return on equity of 7,831.35% and a negative net margin of 493.14%. During the same quarter last year, the business posted ($0.61) EPS. Research analysts forecast that Marinus Pharmaceuticals, Inc. will post -1.93 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have issued reports on MRNS. Truist Financial reaffirmed a “buy” rating and issued a $10.00 target price on shares of Marinus Pharmaceuticals in a research note on Tuesday, June 18th. EF Hutton Acquisition Co. I raised shares of Marinus Pharmaceuticals to a “strong-buy” rating in a report on Monday, September 30th. Oppenheimer upgraded shares of Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 target price on the stock in a research report on Monday, September 23rd. HC Wainwright restated a “buy” rating and set a $11.00 price target on shares of Marinus Pharmaceuticals in a research report on Wednesday, August 14th. Finally, LADENBURG THALM/SH SH downgraded Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Wednesday, August 14th. Four analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $8.83.

Marinus Pharmaceuticals Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.